In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Commentary|Videos|March 19, 2026
Looking Towards the Future of Clinical Trials in Gynecologic Oncology
Author(s)John Moroney, MD, Katherine Kurnit, MD
Fact checked by: Kyle Doherty
John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss which future advances being examined in clinical trials in gynecologic oncology are catching their eyes.
Advertisement
John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss notable ongoing clinical trials in gynecologic oncology at the University of Chicago and beyond. They underscore that many of the most interesting approaches being examined are immunotherapy-based and also highlight trials using cellular therapies.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Sonrotoclax monotherapy produced durable responses in Chinese patients with relapsed/refractory mantle cell lymphoma.
lan M. Thompson Jr., MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
UCSF Health’s Adam Blaisdell, MD, PhD, has been selected as an IGNITE fellow by the Cancer Research Institute.
BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
3
The OncFive: Top Oncology Articles for the Week of 8/2
4
Five Under 5: Top Oncology Videos for the Week of 8/2
5